2024-2025年新冠疫苗效果中期估计——VISION与IVY网络,2024年9月至2025年1月,≥18岁成人
基于VISION和IVY网络,评估2024-2025年新冠疫苗在≥18岁成人中预防急诊/紧急护理就诊及≥65岁成人住院的效果。接种后7-119天,≥18岁成人急诊/紧急护理保护效果为33%(95%CI 28%-38%);免疫正常≥65岁成人住院保护效果为45%(95%CI 36%-53%)和46%(95%CI 26%-60%);免疫受损≥65岁成人住院保护效果为40%(95%CI 21%-54%)。
要点
- ≥18岁成人接种后7-119天,急诊/紧急护理就诊保护效果33%(95%CI 28%-38%)。
- 免疫正常≥65岁成人住院保护效果45%(95%CI 36%-53%)和46%(95%CI 26%-60%)。
- 免疫受损≥65岁成人住院保护效果40%(95%CI 21%-54%)。
核心结论
- 接种2024-2025年新冠疫苗较未接种对急诊/紧急护理就诊和住院提供额外保护,支持CDC和ACIP关于所有≥6月龄人群接种2024-2025年新冠疫苗的建议。
研究设计与样本
- 基于CDC资助的疫苗效果网络,估计2024年9月至2025年1月期间2024-2025年新冠疫苗对≥18岁成人急诊/紧急护理就诊、免疫正常≥65岁成人住院及免疫受损≥65岁成人住院的保护效果。
主要发现
- ≥18岁成人接种后7-119天,对急诊/紧急护理就诊的保护效果为33%(95%CI 28%-38%)。
- 免疫正常≥65岁成人接种后7-119天,两个网络对住院的保护效果分别为45%(95%CI 36%-53%)和46%(95%CI 26%-60%)。
- 免疫受损≥65岁成人接种后7-119天,一个网络对住院的保护效果为40%(95%CI 21%-54%)。
临床怎么用
- CDC和ACIP建议所有≥6月龄人群接种2024-2025年新冠疫苗,该疫苗针对Omicron JN.1及JN.1衍生亚系。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against COVID-19-associated hospitalization among adults aged ≥65 years with immunocompromising conditions in one network. Among adults aged ≥18 years, VE against COVID-19-associated ED/UC visits was 33% (95% CI = 28%-38%) during the first 7-119 days after vaccination. Among immunocompetent adults aged ≥65 years from two CDC networks, VE estimates against COVID-19-associated hospitalization were 45% (95% CI = 36%-53%) and 46% (95% CI = 26%-60%) during the first 7-119 days after vaccination. Among adults aged ≥65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%-54%) during the first 7-119 days after vaccination. These findings demonstrate that vaccination with a 2024-2025 COVID-19 vaccine dose provides additional protection against COVID-19-associated ED/UC encounters and hospitalizations compared with not receiving a 2024-2025 dose and support current CDC and ACIP recommendations that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine dose.
引用
- Link-Gelles R, Chickery S, Webber A, et al. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025. PMID: 40014628. doi:10.15585/mmwr.mm7406a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。